Track market-moving stories before they get noisy

Host Hotels & Resorts, Inc. (HST) Q1 2026 Earnings Call Transcript

Host Hotels & Resorts reported a strong start to 2026, beating Q1 earnings estimates and raising its full-year guidance for adjusted funds from operations. HST maintains a solid financial position with high liquidity and zero debt maturities in 2026 following successful asset sales. Geopolitical risks and administrative backlogs from the recent record-breaking partial government shutdown could pressure the travel industry despite the expected boost from the World Cup.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

It also includes access to the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

#1 (Strong Buy) stocks have produced an unmatched +23.7% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Host Hotels (HST - Free Report) Bethesda, MD-based Host Hotels & Resorts Inc., one of the leading lodging real estate investment trusts (REITs), engages in the ownership, acquisition, and redevelopment of luxury and upper-upscale hotels in the United States and abroad. It is an S&P 500 Index company.

HST is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 10.35; value investors should take notice.

Five analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.05 to $2.10 per share. HST boasts an average earnings surprise of +8.7%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, HST should be on investors' short list.

Host Hotels & Resorts, Inc. (HST) Shareholder/Analyst Call Prepared Remarks Transcript

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

#1 (Strong Buy) stocks have produced an unmatched +23.7% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Host Hotels (HST - Free Report) Bethesda, MD-based Host Hotels & Resorts Inc., one of the leading lodging real estate investment trusts (REITs), engages in the ownership, acquisition, and redevelopment of luxury and upper-upscale hotels in the United States and abroad. It is an S&P 500 Index company.

HST is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

Momentum investors should take note of this Finance stock. HST has a Momentum Style Score of B, and shares are up 7.1% over the past four weeks.

Four analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.04 to $2.10 per share. HST boasts an average earnings surprise of +8.7%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, HST should be on investors' short list.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Host Hotels (HST - Free Report) Bethesda, MD-based Host Hotels & Resorts Inc., one of the leading lodging real estate investment trusts (REITs), engages in the ownership, acquisition, and redevelopment of luxury and upper-upscale hotels in the United States and abroad. It is an S&P 500 Index company.

HST is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 11.54; value investors should take notice.

Four analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.03 to $2.12 per share. HST also boasts an average earnings surprise of +8.7%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, HST should be on investors' short list.

Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization. , /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived DNA (ctDNA). Volition announces the submission of an updated manuscript entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy1".

Volition Team Members Discuss Capture-Seq™ The biggest problem facing liquid biopsy worldwide is that the vast majority of circulating DNA in blood plasma samples comes from healthy cells, not cancer cells. In a world first new technology, Volition has overcome this hurdle and produced >99% pure cancer derived plasma DNA sequence sets for liquid biopsy.

Dr Jake Micallef, Chief Scientific Officer, Volition commented:

"Distinguishing cancer derived plasma DNA from healthy DNA when the two are mixed is problematic. When the cancer DNA makes up 1% or less of the total DNA it is extremely problematic.  Moreover, DNA from cancer and healthy cells has the same double helix structure and has never before been separated chemically.

"Our manuscript, submitted in November and previously announced in December 2025, described a new liquid biopsy chemistry for isolating CTCF-DNA from plasma. Our continuing work on CTCF-bound DNA has revealed what we believe to be an unprecedented new discovery; that there is almost no CTCF-bound DNA in healthy plasma and almost all CTCF-bound DNA in the blood of a cancer patient is derived from cancer cells – i.e. it is virtually pure circulating tumor-derived DNA.

"Removal of background normal cell free DNA from the blood to reveal this level of tumor derived DNA has been a long term goal of liquid biopsy. I believe this is a world-first and could, in my opinion, represent the biggest scientific breakthrough in cancer testing and monitoring in recent years.

"In this updated manuscript we report a new, two-step method for preparing pure circulating tumor DNA data sets for cancer patients:

i.  physical enrichment of the sample and
ii. bioinformatic removal of virtually all remaining non-tumor cfDNA sequences from the DNA sequence data set.

"This new method produced >99% pure ctDNA sequencing data sets for blood samples from cancer patients and, whilst we capture a subset of the ctDNA (i.e. not all the ctDNA in a sample), it is virtually pure cancer DNA.

"These methodological and technological breakthroughs represent a novel liquid biopsy method for a novel class of potentially thousands of liquid biopsy sequence biomarkers.

We call this technology "Capture-Seq™" and it shows potential for both a multi-cancer early detection (MCED) approach, either alone or in combination with other tests, and the detection of Minimal Residual Disease.

"Volition is, I believe, the first liquid biopsy company to focus on circulating cell free nucleoproteins and we have filed a number of new patents to protect this technology."

Dr Andrew Retter, Medical Consultant, Volition commented:

"From a clinical perspective, the proof of concept and early blinded validation results reported in this paper are extremely encouraging. In two independent cohorts we reported no false positives and detected 49/49 cancers in the first cohort (including 23 early stage I/II and 21 controls) and validated it in a second blinded cohort with 13/14 later stage cancers detected with 10 additional controls  We are now working on a further validation cohort of early stage cancers, and expect this data soon.

"For patients, the potential significance is huge. If validated in larger cohorts, CTCF Capture-Seq™ could contribute to multi-cancer early detection and disease management, particularly in combination with Volition's existing Nu.Q® assay for lung cancer (H3K27me3) but potentially in combination with other technologies too."

Mr. Gael Forterre, Chief Commercial Officer, Volition added:

"This scientific breakthrough has generated a lot of interest with potential licensing partners.

"We feel that this technology could, with further development, become very widely used, in both the human and potentially the veterinary market, not only for multi-cancer early detection but also the detection of Minimal Residual Disease.

 "We believe this represents a significant commercial opportunity with a Total Addressable Market on an annualized basis of approximately $23 billion2 for the human MCED use, and over $13 Billion2 for MRD.

"We are in active discussions with several large liquid biopsy and diagnostic companies to accelerate the development and launch of this technology as soon as possible."

The updated paper should be available on the preprint service Research Square in the coming days.

LINK TO Research Square Data on File : Volition TAM Model About Volition

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

Media Enquiries: Louise Batchelor, Volition, [email protected] +44 (0)7557 774620

Safe Harbor Statement

Statements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.

Video - https://www.youtube.com/watch?v=R11jftp4Vcw

SOURCE VolitionRx Limited

Posted by Defense World Staff on Apr 13th, 2026

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report) major shareholder Barry Canton sold 13,116 shares of the firm’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $6.40, for a total transaction of $83,942.40. Following the completion of the sale, the insider owned 338,568 shares in the company, valued at $2,166,835.20. This represents a 3.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Barry Canton also recently made the following trade(s):

On Wednesday, April 8th, Barry Canton sold 13,155 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $6.93, for a total transaction of $91,164.15. Ginkgo Bioworks Price Performance Shares of Ginkgo Bioworks stock opened at $6.46 on Monday. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $5.37 and a fifty-two week high of $17.58. The firm has a market capitalization of $399.76 million, a P/E ratio of -1.14 and a beta of 1.56. The company’s 50 day moving average price is $7.63 and its two-hundred day moving average price is $9.48.

Ginkgo Bioworks (NYSE:DNA – Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported ($1.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.80) by $0.38. Ginkgo Bioworks had a negative net margin of 183.81% and a negative return on equity of 52.82%. The firm had revenue of $33.40 million for the quarter, compared to analyst estimates of $37.57 million. On average, analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.

Analyst Upgrades and Downgrades A number of brokerages have recently commented on DNA. TD Cowen cut their price target on shares of Ginkgo Bioworks from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ginkgo Bioworks in a report on Wednesday, January 21st. Wall Street Zen upgraded shares of Ginkgo Bioworks from a “sell” rating to a “hold” rating in a report on Saturday. Finally, BTIG Research cut their price target on shares of Ginkgo Bioworks from $9.00 to $5.00 and set a “sell” rating on the stock in a report on Thursday, March 12th. One analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average target price of $8.50.

Check Out Our Latest Stock Analysis on DNA

Trending Headlines about Ginkgo Bioworks Here are the key news stories impacting Ginkgo Bioworks this week:

Positive Sentiment: March short interest fell sharply — short interest totaled 6,146,646 shares as of March 31, down 23.2% from 8,004,118 on March 15; roughly 11.0% of the float is sold short and the days-to-cover is ~5.2. Reduced short exposure can remove a headwind and support the stock. Negative Sentiment: Large insider sales by the CEO: Jason R. Kelly sold 97,015 shares on April 8 (avg $6.93) and 109,767 shares on April 9 (avg $6.40), totaling ~206,782 shares (~$1.37M) and materially reducing his holdings. The filings say the sales were to cover tax withholding on vested equity. Jason R. Kelly Form 4 Negative Sentiment: Other insiders/major holders also sold small blocks (Reshma P. Shetty and Barry Canton each sold ~13k shares on April 8–9 at similar prices). These rounds of sales were likewise disclosed as tax-withholding-related. Reshma’s filing: Reshma P. Shetty Form 4; Barry Canton’s filing: Barry Canton Form 4 Hedge Funds Weigh In On Ginkgo Bioworks A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Ginkgo Bioworks by 4.2% during the third quarter. Vanguard Group Inc. now owns 2,480,504 shares of the company’s stock worth $36,166,000 after purchasing an additional 99,379 shares during the period. Erste Asset Management GmbH lifted its holdings in shares of Ginkgo Bioworks by 10.0% during the third quarter. Erste Asset Management GmbH now owns 2,200,000 shares of the company’s stock worth $32,076,000 after purchasing an additional 200,000 shares during the period. Legal & General Group Plc raised its stake in Ginkgo Bioworks by 7.9% during the third quarter. Legal & General Group Plc now owns 1,608,923 shares of the company’s stock worth $23,458,000 after buying an additional 118,402 shares during the last quarter. Millennium Management LLC lifted its holdings in Ginkgo Bioworks by 113.1% in the first quarter. Millennium Management LLC now owns 1,427,600 shares of the company’s stock valued at $8,137,000 after buying an additional 757,535 shares during the period. Finally, State Street Corp lifted its holdings in Ginkgo Bioworks by 38.4% in the fourth quarter. State Street Corp now owns 1,292,071 shares of the company’s stock valued at $10,737,000 after buying an additional 358,231 shares during the period. Institutional investors and hedge funds own 78.63% of the company’s stock.

About Ginkgo Bioworks (Get Free Report)

Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.

The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.

See Also Five stocks we like better than Ginkgo Bioworks

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEInsider Selling: Spire Global (NYSE:SPIR) Chairman Sells $22,422.45 in Stock

NEXT HEADLINE »Spire Global (NYSE:SPIR) CEO Sells $161,462.76 in Stock

Posted by Defense World Staff on Apr 13th, 2026

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report) major shareholder Barry Canton sold 13,155 shares of Ginkgo Bioworks stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $6.93, for a total value of $91,164.15. Following the sale, the insider directly owned 351,684 shares in the company, valued at $2,437,170.12. The trade was a 3.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Barry Canton also recently made the following trade(s):

On Thursday, April 9th, Barry Canton sold 13,116 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $6.40, for a total value of $83,942.40. Ginkgo Bioworks Trading Up 0.1% NYSE DNA opened at $6.46 on Monday. The stock’s 50 day moving average is $7.63 and its two-hundred day moving average is $9.48. The company has a market capitalization of $399.76 million, a price-to-earnings ratio of -1.14 and a beta of 1.56. Ginkgo Bioworks Holdings, Inc. has a 1-year low of $5.37 and a 1-year high of $17.58.

Ginkgo Bioworks (NYSE:DNA – Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The company reported ($1.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.80) by $0.38. The company had revenue of $33.40 million for the quarter, compared to the consensus estimate of $37.57 million. Ginkgo Bioworks had a negative return on equity of 52.82% and a negative net margin of 183.81%. On average, analysts predict that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.

Trending Headlines about Ginkgo Bioworks Here are the key news stories impacting Ginkgo Bioworks this week:

Positive Sentiment: March short interest fell sharply — short interest totaled 6,146,646 shares as of March 31, down 23.2% from 8,004,118 on March 15; roughly 11.0% of the float is sold short and the days-to-cover is ~5.2. Reduced short exposure can remove a headwind and support the stock. Negative Sentiment: Large insider sales by the CEO: Jason R. Kelly sold 97,015 shares on April 8 (avg $6.93) and 109,767 shares on April 9 (avg $6.40), totaling ~206,782 shares (~$1.37M) and materially reducing his holdings. The filings say the sales were to cover tax withholding on vested equity. Jason R. Kelly Form 4 Negative Sentiment: Other insiders/major holders also sold small blocks (Reshma P. Shetty and Barry Canton each sold ~13k shares on April 8–9 at similar prices). These rounds of sales were likewise disclosed as tax-withholding-related. Reshma’s filing: Reshma P. Shetty Form 4; Barry Canton’s filing: Barry Canton Form 4 Institutional Inflows and Outflows Institutional investors and hedge funds have recently modified their holdings of the business. Erste Asset Management GmbH boosted its holdings in shares of Ginkgo Bioworks by 10.0% in the 3rd quarter. Erste Asset Management GmbH now owns 2,200,000 shares of the company’s stock worth $32,076,000 after acquiring an additional 200,000 shares in the last quarter. Jump Financial LLC acquired a new position in shares of Ginkgo Bioworks in the 2nd quarter worth approximately $4,163,000. Allianz Asset Management GmbH acquired a new position in shares of Ginkgo Bioworks in the 3rd quarter worth approximately $2,802,000. SPX Gestao de Recursos Ltda bought a new position in Ginkgo Bioworks in the 3rd quarter worth approximately $1,458,000. Finally, Green Alpha Advisors LLC raised its position in Ginkgo Bioworks by 10.6% in the 4th quarter. Green Alpha Advisors LLC now owns 14,327 shares of the company’s stock worth $119,000 after purchasing an additional 1,378 shares during the last quarter. 78.63% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes DNA has been the topic of a number of recent research reports. BTIG Research decreased their price objective on Ginkgo Bioworks from $9.00 to $5.00 and set a “sell” rating on the stock in a report on Thursday, March 12th. TD Cowen reduced their target price on Ginkgo Bioworks from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ginkgo Bioworks in a report on Wednesday, January 21st. Finally, Wall Street Zen raised Ginkgo Bioworks from a “sell” rating to a “hold” rating in a report on Saturday. One research analyst has rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus price target of $8.50.

Get Our Latest Report on DNA

Ginkgo Bioworks Company Profile (Get Free Report)

Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.

The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.

See Also Five stocks we like better than Ginkgo Bioworks

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEInsider Selling: Spire Global (NYSE:SPIR) CTO Sells $108,817.21 in Stock

NEXT HEADLINE »Primoris Services (NYSE:PRIM) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.

Completed acquisition of the DNA X cryptocurrency trading platformClosed sale of the Company's mobile device assets to NEXA in January 2026Focused on enhancing the DNA X trading platform to prepare the platform for its initial growth phaseSan Diego, California--(Newsfile Corp. - April 14, 2026) - DNA X, Inc. (NASDAQ: SONM), a provider of cryptocurrency trading services, today announced its financial results for the fourth quarter and full year ended December 31, 2025.

The company purchased the DNA X cryptocurrency trading platform business in December 2025, following the launch of the DNA X.us website in November 2025 that is now active. The platform is designed to take advantage of movements between pairs of cryptocurrencies and to allow clients to automate trading strategies that automatically take advantage of converging and diverging pairs of cryptocurrency values.

The Company completed the sale of its mobile device design and manufacturing business to NEXA Mobility, a private company in the hardware space on January 23, 2026. The sale allows the Company to focus on the DNA X trading platform and its growth potential. The purchase price of the assets was $15 million less customary working capital adjustments with $13.5 million being paid immediately and $1.5 million in cash to be paid in nine months. The company used the proceeds to repay debt and other obligations. The remaining cash will be used to support the DNA X trading business.

On January 23, 2026, the Company successfully rebranded itself as DNA X, Inc., from Sonim Technologies Inc. The stock ticker on Nasdaq remains SONM and our primary corporate offices remain in San Diego.

On January 30, 2026, our Chief Executive Officer and board member resigned and our Executive Chairman became the acting Chief Executive Officer. A new board member, Scott Walker, a co-founder of DNA Holdings (the company that sold us the DNA X trading platform), was appointed to the board on January 30, 2026. Scott brings vast expertise in the cryptocurrency trading industry.

"We have transitioned to an industry that we believe is in its infancy and provides us with great opportunities for growth," said Mike Mulica, acting Chief Executive Officer. "We are very excited about the growth opportunity that we see in front of us."

Fourth Quarter 2025 Financial Highlights:

Revenue: There was no revenue from continuing operations because revenue from our phone and hotspot operations was included in discontinued operations.General & Administrative Expenses: Fourth-quarter general and administrative expenses for continuing operations were $1.2 million and were primarily due to legal costs for the acquisition of the DNA X trading platform, legal costs for the asset sale, and proxy costs for the special stockholders' vote for the asset sale. Cash Position: We ended the year with $1.3 million in cash from continuing operations. This cash plus cash proceeds from the asset sale will be used to support and grow the DNA X trading business.2025 Business Highlights: We successfully purchased the DNA X trading platform and we positioned the Company to complete the sale of our mobile device assets in January 2026. These transitions allowed us to move away from the geo-political risks that drastically raised the costs to produce our phones and hotspots as we moved our production outside of China, became subject to tariffs, and as supply chain costs increased. Notable accomplishments include:

Integrated the DNA X trading business with our existing infrastructureBegan the integration of our phone and hotspot business with the Buyer to achieve a desired sale price for the asset sale that we completed in January 2026Developed a transition plan to ensure that we have necessary leadership and expertise to manage the DNA X trading business once the phone and hotspot assets were sold2026 Outlook: "We expect future growth in revenue, gross margin and profitability as we exit the monitoring and testing phase and begin marketing our trading platform to the public," said Clay Crolius, CFO of DNA X. "With product enhancements and an increase in the number of cryptocurrencies that can be traded, we believe we are uniquely positioned to grow while increasing our margins."

About DNA X, Inc. DNA X operates a decentralized finance (DeFi) protocol that automates trading on decentralized exchanges, including recurring and limit orders. For more information, visit https://ir.dna-x.global.

Media and Investor Relations Contact: Clay Crolius, DNA X, Inc. [email protected].

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that do not relate to matters of historical fact are forward-looking statements, including, without limitation, statements regarding the Company's strategic transformation, the expected growth, performance and market opportunities of the DNA X trading platform, anticipated use of proceeds from the sale of the Company's mobile device design and manufacturing business, and the Company's future operations and financial performance.

These forward-looking statements are based on the Company's current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to: risks related to the Company's ability to successfully integrate and operate the DNA X trading platform and achieve anticipated growth; the early-stage nature of the Company's current business and the volatility of the cryptocurrency markets; the Company's recent disposition of its mobile device design and manufacturing business; the Company's ability to obtain or maintain sufficient liquidity to execute its business plan; potential delays or challenges in executing its strategic plans; general economic, market and industry conditions; and the Company's ability to maintain compliance with Nasdaq listing requirements.

Additional information regarding these and other risks and uncertainties is included in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company cautions you not to place undue reliance on forward-looking statements, which speak only as of the date of this press release, and undertakes no obligation to update such statements, except as required by law.

DNA X, INC.
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2025 and 2024
(IN THOUSANDS EXCEPT SHARE AND PER SHARE AMOUNTS)

December 31, 2025
December 31, 2024
Assets

Cash and cash equivalents$1,303
$5,343
Prepaid expenses and other current assets
676

-
Current assets held for sale
26,930

26,822
Total Current assets
28,909

32,165
Investment in DNA X, LLC
1,242

-
Deferred tax assets
1,441

64
Other assets
274

384
Non-current assets held for sale
12,032

7,126
Total assets$43,898
$39,739
Liabilities and stockholders' deficit
 

 
Accounts payable
4,030

738
Accrued liabilities
704

250
Promissory notes, net
5,065

-
Derivative liability on convertible note
171

-
Current liabilities held for sale
38,057

42,752
Total current liabilities
48,027

43,740
Income tax payable
2,598

1,699
Total liabilities
50,625

45,439
Commitments and contingencies
-

-

 

 
Redeemable common stock, $0.001 par value; 223,201 shares issued and outstanding; redemption value $1,228
1,228

-

 

 
Stockholders' deficit
 

 
Common stock, $0.001 par value per share; 1,000,000,000 shares authorized: and 1,265,067 and 276,881 shares issued and outstanding at December 31, 2025 and 2024, respectively*
1

-
Preferred stock, $0.001 par value per share, 5,000,000 shares authorized: and no shares issued and outstanding at December 31, 2025 and 2024
-

-
Additional paid-in capital*
296,309

277,908
Accumulated deficit
(304,265)
(283,608)Total stockholders' deficit
(7,955)
(5,700)Total liabilities, redeemable common stock, and stockholders' deficit$43,898
$39,739
     * Adjusted retroactively to reflect the 1-for-18 reverse stock split that became effective on October 28, 2025.    DNA X, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
YEARS ENDED DECEMBER 31, 2025 and 2024
(IN THOUSANDS EXCEPT SHARE AND PER SHARE AMOUNTS)

2025
2024
Continuing operations:

Net revenues$-
$-
Cost of revenues
-

-
Gross profit
-

-
Operating expenses
 

 
General and administrative
5,406

3,100
Other
-

-
Total operating expenses
5,406

3,100
Net income (loss) from operations
(5,406)
(3,100)Interest expense, net
(1,486)
(29)Loss on extinguishment of debt
(161)
-
Other income (expense), net
(902)
246
Net loss from continuing operations before income taxes
(7,955)
(2,883)Income tax expense from continuing operations
-

-
Net loss from continuing operations
(7,955)
(2,883)Discontinued Operations:
 

 
Loss from discontinued operations, net of tax
(12,702)
(30,765)Net loss$(20,657)$(33,648)Net loss per share basic and diluted:
 

 
Continuing operations*
(11.00)
(11.00)Discontinued operations*
(17.58)
(117.37)Net loss*$(28.58)$(128.37)Weighted-average shares used in computing net loss per share:
 

 
Basic and diluted*
722,689

262,118
       * Adjusted retroactively to reflect the 1-for-18 reverse stock split that became effective on October 28, 2025.    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/292277

Source: DNA X, Inc. (formerly Sonim Technologies Inc.)

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business

, /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the first quarter of 2026 that ended March 31, 2026. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com.

First Quarter 2026 Financial Results

As previously announced, Ginkgo completed the divestiture of its Biosecurity business on April 3, 2026 and is presenting the financial results of operations for the former business within discontinued operations.  Accordingly, Ginkgo's previously reported financial results for comparable periods have been retrospectively recast to conform to this presentation and reflect Ginkgo as a single reporting segment. First quarter 2026 Revenue of $19 million compared to $38 million in the comparable prior year period, a decrease of 49%. As previously reported, the first quarter of 2025 benefited from $7 million of non-cash revenue from previously announced release of deferred revenue relating to the mutual termination of a customer agreement. Excluding this non-cash deferred revenue release, first quarter 2026 Revenue of $19 million, down from $31 million in the comparable prior year period, a decrease of 37%. The decrease in revenue is primarily attributed to ongoing program rationalization as part of our restructuring activities. First quarter 2026 GAAP net loss from continuing operations of $(76) million, compared to $(83) million in the comparable prior year period. First quarter 2026 Adjusted EBITDA of $(42) million, down from $(44) million in the comparable prior year period. Cash, cash equivalents and marketable securities balance as of March 31, 2026 of $373 million. "We believe autonomous labs will replace the lab bench more quickly than people think," said Jason Kelly, Co-founder and CEO of Ginkgo Bioworks. "Nebula is already the world's largest autonomous lab with the ability to run real customer science around the clock and we're targeting to double its size this year. We see a large market that remains overwhelmingly manual today, and every experiment our Solutions, Datapoints, and Cloud Lab businesses run on Nebula generates revenue today while making the platform better for tomorrow. Ginkgo is singularly focused on leading the transition from the lab bench to autonomous research infrastructure that runs 24/7 and integrates directly with the AI models transforming drug discovery and industrial biotechnology."

Recent Business Highlights & Strategic Positioning

We believe that autonomous labs will replace the bench. The return on investment of the autonomous lab is clear for customers, with millions of square feet and tens of billions per year being spent on work happening at the lab bench The autonomous lab is a machine that can run 24/7 and can be seamlessly integrated into emerging AI models Nebula, our autonomous lab, is showing what is possible at the bleeding edge. Nebula is the world's largest autonomous lab and in 2026 we are aiming to double its size Recent coverage positions Ginkgo at the frontier of scientific innovation in the scientific (Nature), trade (R&D World), mainstream (Forbes, The Washington Post), and tech press (Sequoia's Training Data, TBPN) Policymakers and heads of R&D visit for our internal demonstrations. During SLAS 2026, over 500 visitors came to tour Nebula Cloud Lab, Datapoints, and Solutions are our version of Starlink. They both create revenue and speed the development of the autonomous lab We are seeing traction with our Cloud Lab from partners such as ProQR and Amazon, who included us as an integrated wet lab partner on their Amazon Bio Discovery platform Full Year 2026 Outlook

Ginkgo reaffirms expected total cash burn of $(150)-$(125) million in 2026.   Conference Call Details
Ginkgo will host a videoconference today, Thursday, May 7, beginning at 4:30 p.m. ET. The presentation will include an overview of the first quarter 2026, recent business updates, a discussion on Ginkgo's outlook, as well as a moderated question and answer session. 

To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to [email protected].

A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation.

Ginkgo Investor Website: https://investors.ginkgobioworks.com/events/

Audio-Only Dial Ins:

+1 646 876 9923 (New York - ET)
+1 301 715 8592 (Washington DC - ET)
+1 305 224 1968 (Miami - ET)
+1 689 278 1000 (Orlando - ET)
+1 312 626 6799 (Chicago - CT)
+1 507 473 4847 (Minnesota - CT)
+1 346 248 7799 (Houston - CT)
+1 719 359 4580 (Colorado - MT)
+1 408 638 0968 (San Jose - PT)
+1 564 217 2000 (Seattle - PT)

Webinar ID: 931 5925 7666

If you experience technical difficulties with any of these dial-ins or if you need international dial-in numbers, please visit our website at https://investors.ginkgobioworks.com/events/ for updated dial-in information.

About Ginkgo Bioworks
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo's in-house autonomous lab is also available as a "Cloud Lab" through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com, read our blog, or follow us on social media channels such as X (@Ginkgo), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.

Forward-Looking Statements of Ginkgo Bioworks 
This press release, the presentation, and the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, including with respect to technology adaptations to meet our customers' needs and the integration of our autonomous lab platform with third-party artificial intelligence models, strategies, including with respect to our current expectations, operations and anticipated results of operations, both business and financial, including the timing for attaining Adjusted EBITDA breakeven, potential customer success, including successful application of our offerings by our customers, expected benefits from our strategic partnerships and collaborations (including with named partners such as ProQR and Amazon), the anticipated growth, scaling, capacity, capabilities and competitive position of our autonomous lab (including Nebula) and of our Cloud Lab, Datapoints and Solutions offerings, our beliefs and estimates regarding the size, composition, growth and pace of adoption of the market for autonomous laboratory and related services (including the displacement of manual laboratory work), expectations regarding the development, performance and future enhancements of our platform, and expectations with regard to revenue, including our ability to meet all milestones and achieve the maximum revenue available under certain of our customer arrangements, expenses, our full year 2026 outlook including the total cash burn guidance, and the market environment, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," "target," "goal," "aim," "design," "forecast," "outlook," "guidance," "seek" "position," and similar expressions, as well as the negatives of such terms. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our platform programs and assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith, (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies, including potential adverse effects from the U.S. government shutdown, (xiv) our ability to scale, expand the capacity of, and continue to develop the capabilities of our autonomous lab (including Nebula) on the timelines and to the extent we anticipate, (xv) the pace and degree to which autonomous laboratory infrastructure is adopted by, and displaces manual laboratory work in, the broader life sciences and industrial biotechnology markets, (xvi) the actual size, composition and growth of the addressable markets we target, which may differ materially from our estimates, (xvii) our ability to integrate our autonomous lab platform with third-party artificial intelligence models and other technologies, and the rate of development and adoption of such technologies, and (xviii) our ability to maintain and expand strategic partnerships and customer relationships, including those with named partners referenced in this release. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 26, 2026 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

Use of Non-GAAP Financial Measures
Certain of the financial measures included in this release, including Adjusted EBITDA, cash flow and cash burn, have not been prepared in accordance with generally accepted accounting principles ("GAAP"), and constitute "non-GAAP financial measures" as defined by the SEC. Ginkgo has included these non-GAAP financial measures because it believes they provide an additional tool for investors to use in evaluating Ginkgo's financial performance and prospects. Due to the nature and/or size of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of our future operating performance. These non-GAAP financial measures are supplemental to, and should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the reconciliation below for additional information regarding certain of the non-GAAP financial measures included in this release, including a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo's most comparable GAAP financial measures. Ginkgo does not reconcile its forward-looking non-GAAP financial measures to the corresponding GAAP measures, due to variability and difficulty in making accurate forecasts and projections and/or certain information not being ascertainable or accessible; and because not all of the information, such as unrealized equity gains and losses necessary for a quantitative reconciliation of these forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measure, can be predicted with reasonable accuracy and is available to Ginkgo without unreasonable efforts. For the same reasons, Ginkgo is unable to address the probable significance of the unavailable information. Ginkgo provides non-GAAP financial measures that it believes will be achieved, however it cannot accurately predict all of the components of the adjusted calculations and the GAAP measures may be materially different than the non-GAAP measures.

Ginkgo Bioworks Contacts: 

INVESTOR CONTACT:
[email protected] 

MEDIA CONTACT:
[email protected]

Ginkgo Bioworks Holdings, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands, except share data)

As of March 31,
2026

As of December 31,
2025

Assets

Current assets:

Cash and cash equivalents

$             143,864

$             167,202

Marketable securities

229,592

255,418

Accounts receivable, net

19,815

24,026

Accounts receivable - related parties

454

229

Prepaid expenses and other current assets

16,230

24,963

Total current assets

409,955

471,838

Property, plant and equipment, net

163,020

167,371

Operating lease right-of-use assets

353,804

360,918

Investments

14,703

15,066

Intangible assets, net

48,860

53,482

Other non-current assets

39,522

47,167

Assets held for sale

3,211

3,854

Total assets

$           1,033,075

$           1,119,696

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable

$              16,309

$              10,566

Deferred revenue (includes $98 and $98 from related parties)

14,910

18,946

Accrued expenses and other current liabilities

48,376

66,458

Total current liabilities

79,595

95,970

Non-current liabilities:

Deferred revenue, net of current portion (includes $64,810 and $64,787 from related
parties)

77,895

75,182

Operating lease liabilities, non-current

410,700

417,078

Other non-current liabilities

21,732

22,876

Total liabilities

589,922

611,106

Commitments and contingencies (Note 10)

Stockholders' equity:

Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued

—

—

Common stock, $0.0001 par value (Note 8)

6

6

Additional paid-in capital

6,674,860

6,657,053

Accumulated deficit

(6,232,907)

(6,150,320)

Accumulated other comprehensive income

1,194

1,851

Total stockholders' equity

443,153

508,590

Total liabilities and stockholders' equity

$           1,033,075

$           1,119,696

Ginkgo Bioworks Holdings, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(unaudited)

(in thousands, except share data)

Three Months Ended March
31,

2026

2025

Revenue (1)

$        19,474

$        38,230

Costs and operating expenses:

Cost of other revenue

3,098

4,090

Research and development

49,920

70,923

General and administrative

37,830

39,723

Restructuring charges

—

4,466

Total operating expenses

90,848

119,202

Loss from operations

(71,374)

(80,972)

Other income (expense):

Interest income, net

3,596

6,081

Loss on investments

(1,214)

(3,693)

Other expense, net

(7,147)

(4,638)

Total other expense

(4,765)

(2,250)

Loss from continuing operations before income taxes

(76,139)

(83,222)

Income tax (benefit) expense

(80)

88

Net loss from continuing operations

$       (76,059)

$       (83,310)

Net loss from discontinued operations, net of tax

(6,528)

(7,647)

Net loss

$       (82,587)

$       (90,957)

Net loss per share:

Basic from continuing operations

$           (1.28)

$           (1.54)

Basic from discontinued operations

(0.11)

(0.14)

Basic

$           (1.39)

$           (1.68)

Weighted average common shares outstanding:

Basic

59,563,454

54,241,619

Comprehensive loss:

Net loss

(82,587)

(90,957)

Other comprehensive (loss) income:

Foreign currency translation adjustment

(579)

849

Unrealized gains (loss) on available-for-sale securities          

(78)

107

Total other comprehensive (loss) income

(657)

956

Comprehensive loss

$       (83,244)

$       (90,001)

(1)  includes related party revenue of zero and $8,098 for the three months ended March 31, 2026 and 2025, respectively.

Ginkgo Bioworks Holdings, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

Three Months Ended March 31,

2026

2025

Cash flows from operating activities:

Net loss from continuing operations

$       (76,059)

$       (83,310)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

12,799

14,822

Stock-based compensation

15,853

17,386

Loss on investments

1,214

3,693

Change in fair value of notes receivable

6,759

5,285

Change in fair value of contingent consideration

—

(1,302)

Non-cash lease expense

7,114

7,379

Accretion of discount on marketable securities

(120)

—

Other non-cash activity

185

149

Changes in operating assets and liabilities:

Accounts receivable

(242)

(667)

Prepaid expenses and other current assets

5,930

(581)

Operating lease right-of-use assets

—

3,675

Other non-current assets

94

(167)

Accounts payable, accrued expenses and other current liabilities

(11,601)

8,869

Deferred revenue, current and non-current (includes zero and $(7,878) from related
parties)

(2,606)

(13,190)

Operating lease liabilities, current and non-current

(4,995)

(4,790)

Other non-current liabilities

(758)

—

Net cash used in operating activities - continuing operations

(46,433)

(42,749)

Net cash used in operating activities - discontinued operations

(253)

(8,772)

Net cash used in operating activities

(46,686)

(51,521)

Cash flows from investing activities:

Purchases of marketable debt securities

(83,161)

(191,182)

Maturities of marketable debt securities

108,178

—

Purchases of property and equipment

(1,933)

(7,622)

Other

48

120

Net cash provided by (used in) investing activities

23,132

(198,684)

Cash flows from financing activities:

Principal payments on finance leases

(19)

(207)

Net cash used in financing activities

(19)

(207)

Effect of foreign exchange rates on cash and cash equivalents

(129)

74

Net decrease in cash, cash equivalents and restricted cash

(23,702)

(250,338)

Cash and cash equivalents, beginning of period

167,202

561,572

Restricted cash, beginning of period

45,169

44,171

Cash, cash equivalents and restricted cash, beginning of period

212,371

605,743

Cash and cash equivalents, end of period

143,864

312,420

Restricted cash, end of period

44,805

42,985

Cash, cash equivalents and restricted cash, end of period

$       188,669

$       355,405

The following table presents summary results of the Company's reportable segment, including significant expenses, and a reconciliation to loss from continuing operations before income taxes (in thousands):

Three Months Ended March 31,

2026

2025

Revenue

$        19,474

$        38,230

Costs and operating expenses:

   Cost of other revenue (1)

2,672

3,121

   Research and development (1)

30,105

48,670

   General and administrative (1)

12,723

19,654

Stock-based compensation (2)

16,708

17,713

Depreciation and amortization

12,799

14,822

Restructuring charges (3)

—

4,466

Carrying cost of excess space (net of sublease income) (4)

15,842

11,674

Merger and acquisition related expense (income) (5)

—

(918)

Other (income) expense, net (6)

4,764

2,250

Loss from continuing operations before income taxes

$      (76,139)

$      (83,222)

(1)

The costs and operating expenses exclude expenses which are separately captioned below.

(2)

Includes $0.9 million and $0.4 million in employer payroll taxes for three months ended March 31, 2026 and 2025, respectively.

(3)

See Note 3, Restructuring, for composition of costs.

(4)

The carrying cost of excess space includes base rent, common area maintenance charges, and real estate taxes associated with facilities the Company is not occupying, net of any sublease income from these spaces.

(5)

Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) legal, consulting, and accounting fees associated with acquisitions; (ii) post-acquisition employee retention bonuses; (iii) (gain)/loss from changes in the fair value of contingent consideration liabilities resulting from acquisitions; and (iv) securities litigation costs.

(6)

Includes interest income, interest expense, loss on investments, changes in fair value of certain assets and liabilities, and other gains and losses.

Three Months Ended March 31,

(in thousands)

2026

2025

Net loss from continuing operations (1)

$      (76,059)

$      (83,310)

Interest income, net

(3,596)

(6,081)

Income tax (benefit) expense

(80)

88

Depreciation and amortization

12,799

14,822

EBITDA

(66,936)

(74,481)

Stock-based compensation (2)

16,708

17,713

Restructuring charges (3)

—

4,466

Merger and acquisition related (income) expense (4)          

—

(918)

Loss (gain) on investments

1,214

3,693

Change in fair value of notes receivable

6,759

5,285

Adjusted EBITDA

$      (42,255)

$      (44,242)

(1)

All periods include non-cash revenue when earned, including $7.5 million recognized in the three months ended March 31, 2025, pursuant to the release of deferred revenue related to the mutual termination of a customer agreement.

(2)

Includes $0.9 million and $0.4 million  in employer payroll taxes for the three months ended March 31, 2026 and 2025, respectively.

(3)

Restructuring charges primarily consist of employee termination costs from the reduction in force commenced in June 2024.

(4)

Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) legal, consulting, and accounting fees associated with acquisitions; (ii) post-acquisition employee retention bonuses; (iii) (gain)/loss from changes in the fair value of contingent consideration liabilities resulting from acquisitions; and (iv) securities litigation costs. Not included in this adjustment are acquired in-process research and development expenses, which totaled zero for both the three months ended March 31, 2026 and 2025, respectively.

SOURCE Ginkgo Bioworks

Focus 2030 targets market competitiveness and sustainable business operations through brand reinforcement and unification, close partner collaboration, financial discipline, and multi-powertrain strategy.New proprietary X-Hybrid performance technology will be the first of its kind to come to market in Europe in Q4 2026, with more than 1,000 orders in China in the first month for Eletre X - showing early momentum.Type 135 confirmed as an all-new hybrid-V8 supercar coming to market in 2028, reaffirming Lotus’ performance DNA. NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Lotus Technology Inc. (“Lotus Tech” or the “Company”) (Nasdaq: LOT), a leading global intelligent and luxury mobility provider, today announced Focus 2030 for Lotus, an evolved business strategy designed to underpin its competitiveness and transformation into a more flexible and sustainable business model ensuring market resilience amid external headwinds.

Built on four core pillars, including brand reinforcement, a multi-powertrain strategy, close partner collaboration, and financial discipline, the strategy marks a significant reset for the brand.

Mr. Qingfeng Feng, Chief Executive Officer of Lotus Tech, said, “Lotus was born from the rebellious spirit of Colin Chapman, and that is not lost today. Focus 2030 will reset both the brand and the business, keeping us true to our DNA. We are obsessed with engineering, performance and building drivers' cars, and that is what will grow this business.”

Protecting What Makes Lotus, Lotus
Focus 2030 puts the Lotus DNA at the heart of every decision. Regardless of product or powertrain, every Lotus has been, and will be, developed against the same set of guiding principles: lightweight design, aerodynamics, obsessive engineering, and driver engagement.

Lotus has been instrumental in shaping automotive culture for 78 years - redefining the limits of performance in racing and building the most engaging road cars in the world. This continues under Focus 2030, with design and engineering rooted in the UK, home of the brand’s identity and motorsport expertise, and R&D in China to deliver rapid scale to market.

Multi-Powertrain Strategy, Built Around the Customer
As regulatory and consumer landscapes continue to evolve globally at different speeds, Lotus will pursue an agile approach across ICE (internal combustion engine), PHEV (hybrid electric vehicle), and BEV (battery electric vehicle), targeting an approximately 60:40 mix between PHEV and BEV volume mix over its electrified portfolio in the interim, and a customer-led transition to full electrification.

Hybrid technology will play a central role, serving specific customer needs. First to come is X-Hybrid, a unique blend of ICE and BEV performance expertise that delivers long-range, flexibility, and practicality alongside sustained high performance and Lotus’ trademark driver engagement.

Lotus’ proprietary X-Hybrid technology was first launched on Eletre, as Eletre X (known as “For Me” in China). Customer deliveries have started in China, and early vehicle reception has been positive, with more than 1,000 orders placed in the first month alone. Customer deliveries in Europe are expected to begin in Q4 2026, making it the first of its kind to come to market.

Reaffirming the brand’s performance DNA, the next development of Lotus’ proprietary hybrid technology will be the unveiling of its first-ever supercar, Type 135 (also known as “Vision X”), planned for delivery in 2028. This will be an all-new car, featuring a V8 hybrid powertrain, with over 1000PS. It is expected to be manufactured in Europe, with further details to be announced later this year.

Emira continuity is confirmed, reflecting both Lotus’ commitment to manufacturing in the UK and sustained consumer demand for its combustion-engine sportscars. The company will reveal an update in the coming weeks, designed to be the most powerful and lightest Emira ever built.

Lotus’ BEV portfolio, Eletre (SUV), Emeya (GT), and Evija (Hypercar), remains a core pillar of the business, having brought new customers to the marque and broadened its commercial foundation. Lotus was an early adopter of 800V architecture through its electric SUV and GT offerings and remains committed to continued BEV innovation.

Built to Compete Globally
Lotus’ close collaboration with its major shareholder, Geely Holding Group, is central to Focus 2030. The two businesses are working together on technology development, supply-chain competitiveness, and manufacturing efficiencies to increase go-to-market speed, global scale, and margin resilience.

The partnership gives Lotus access to world-class electrification capabilities and resources, while Lotus contributes its globally recognized performance engineering expertise and brand equity to Geely Holding Group’s portfolio.

Underpinning this is the planned integration of Lotus UK and Lotus Tech into a single entity, which is expected to unify the brand, streamline governance, reduce costs, and accelerate engineering integration for next-generation performance vehicles.

Daniel Li, Chairman of the Board of Directors at Lotus Tech, and Executive Vice Chairman of Geely Holding Group, said, “Geely has believed in Lotus from the beginning, and that belief has not wavered. We are committed to giving Lotus the resources it deserves to compete at the highest level. What Lotus brings is irreplaceable, and Focus 2030 is proof that we take that responsibility seriously. We are excited for the next chapter in the brand's story."

Restoring Financial Discipline
Focus 2030 sets a clear commercial direction for the business, with a focus on targeted volumes, stronger margins, and greater emphasis on personalization. Lotus is guiding towards a steady ramp-up to 30,000 sales units annually as its full model line-up stabilizes, enabling the business to reach sustained profitability.

Over the last year, Lotus has made significant improvements across its entities to increase operational efficiency. Lotus Tech has also increased cost optimization and operational efficiency, as demonstrated by its improved margins in its full-year 2025 results.

The Company has targeted a clear and diverse strategy across its core markets:

China - the primary volume growth engine, leveraging strong demand for premium new energy vehicles (NEV).Europe - building on racing heritage and British engineering brand equity across a diverse powertrain portfolio.North America - strategy anchored in sports cars, with a new SUV market opportunity in Canada.APAC and Middle East - foundations have been developed, and the brand is now active in 25 markets across the region, providing opportunities to reach new customers with its entire product portfolio. About Lotus Technology Inc. 
Lotus Technology Inc. has operations across the UK, the EU and China. The Company is dedicated to delivering luxury lifestyle electric vehicles, with a focus on world-class R&D in next-generation automobility technologies such as electrification, digitalization and more. For more information about Lotus Technology Inc., please visit www.group-lotus.com.

Forward-Looking Statements
This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential”, “forecast”, “plan”, “seek”, “future”, “propose” or “continue”, or the negatives of these terms or variations of them or similar terminology although not all forward-looking statements contain such terminology. Forward-looking statements involve inherent risks and uncertainties, including those identified under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and Lotus Technology Inc. undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Contact Information
For investor inquiries
[email protected]

For media inquiries
[email protected]

Ginkgo Bioworks (DNA) reported Q1 revenues of $19.5M, down nearly 50% year-over-year and badly missing street estimates even after Biosecurity adjustments. Management is pivoting to autonomous labs but refuses to provide revenue guidance, causing analyst estimates to fall further. DNA continues to burn significant cash, with Q1 cash burn at $49M and 2026 guidance of $125M–$150M, leaving $373M in cash and no debt but weakening flexibility.

Closed sale of the Company's mobile device assets to NEXA in January 2026Completed the transfer of the operations of the phone and hotspot business to NEXAFocused on enhancing the DNA X trading platform to prepare the platform for its initial growth phaseSan Diego, California--(Newsfile Corp. - May 20, 2026) - DNA X, Inc. (NASDAQ: SONM), a provider of cryptocurrency trading services, today announced its financial results for the first quarter ended March 31, 2026.

The company operates the DNA X AI trading platform business, and expects to launch an enhanced version to the public later this year. The platform is designed to harness advanced AI and machine learning technologies to automate intelligent trading strategies, enabling clients to capitalize on data-driven insights and dynamic opportunities.

The Company completed the sale of its mobile device design and manufacturing business to NEXA Mobility, a private company in the hardware space on January 23, 2026. The purchase price of the assets was $15 million less a working capital adjustment of $1.5 million, with $12.0 million being paid immediately and the remaining cash of $1.5 million, less any agreed upon claims, to be paid in October 2026. The company used the proceeds to repay debt and other obligations. The remaining cash will be used to support the DNA X AI trading business.

On January 23, 2026, the Company successfully rebranded itself as DNA X, Inc., from Sonim Technologies Inc. The stock ticker on Nasdaq remains SONM and our primary corporate offices remain in San Diego.

The asset sale resulted in $6.3 million in net income for the first quarter of 2026, net of taxes, transaction fees, and severance costs.

"Having successfully completed a strategic exit from our legacy business, management has made a deterministic decision to reallocate our resources into the high-growth, high-margin decentralized AI and crypto trading sectors," said Mike Mulica, acting Chief Executive Officer. "This pivotal transition marks the beginning of our value build phase, positioning DNA X to deliver sustainable, long-term value for our shareholders through AI and crypto trading innovation."

First Quarter 2026 Financial Highlights:

Revenue: There was no revenue from continuing operations because revenue from our phone and hotspot operations was included in discontinued operations. Our AI platform activities are accounted for as an investment and are reflected as other income.General & Administrative Expenses: First-quarter general and administrative expenses from continuing operations were $3.6 million and included one time severance costs of $1.5 million and $0.9 million in professional services for our annual audit and tax services. We expect general & administrative expenses to be much lower in the next few quarters because we have downsized the organization and we have completed our annual audit. Cash Position: We ended the quarter with $1.2 million in cash from continuing operations. On May 20, 2026 we entered into an agreement to raise an additional $1.8 million in cash by issuing new debt. This cash will be used for working capital purposes and to support and grow the DNA X AI and crypto trading business.About DNA X, Inc. DNA X operates an advanced artificial intelligence platform that automates complex workflows and decision-making using state-of-the-art AI models. For more information, visit https://ir.dna-x.global.

Media and Investor Relations Contact: Clay Crolius, DNA X, Inc. [email protected].

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that do not relate to matters of historical fact are forward-looking statements, including, without limitation, statements regarding the Company's strategic transformation, the expected growth, performance and market opportunities of the DNA X trading platform, anticipated use of proceeds from the sale of the Company's mobile device design and manufacturing business, and the Company's future operations and financial performance.

These forward-looking statements are based on the Company's current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to: risks related to the Company's ability to successfully integrate and operate the DNA X trading platform and achieve anticipated growth; the early-stage nature of the Company's current business and the volatility of the cryptocurrency markets; the Company's recent disposition of its mobile device design and manufacturing business; the Company's ability to obtain or maintain sufficient liquidity to execute its business plan; potential delays or challenges in executing its strategic plans; general economic, market and industry conditions; and the Company's ability to maintain compliance with Nasdaq listing requirements.

Additional information regarding these and other risks and uncertainties is included in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company cautions you not to place undue reliance on forward-looking statements, which speak only as of the date of this press release, and undertakes no obligation to update such statements, except as required by law.

DNA X, INC.
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS EXCEPT SHARE AND PER SHARE AMOUNTS)

March 31,
2026
December 31,
2025

(Unaudited)

Assets

Cash and cash equivalents$1,195
$1,303
Receivable for cash held back from the asset sale
1,500

—
Prepaid expenses and other current assets
608

676
Current assets held for sale
—

26,930
Total Current assets
3,303

28,909
Investment in DNA X LLC under equity method
1,290

1,242
Deferred tax assets
—

1,441
Other assets
245

274
Non-current assets held for sale
—

12,032
Total assets$4,838
$43,898
Liabilities and stockholders' deficit
 

 
Accounts payable
719

4,030
Accrued liabilities
1,576

704
Promissory note, net from related party
1,072

1,035
Promissory notes, net
—

4,030
Derivative liability
398

171
Income tax payable
556

2,598
Current liabilities held for sale
—

38,057
Total current liabilities
4,321

50,625
Deferred tax liability
600

—
Total liabilities
4,921

50,625
Commitments and contingencies
—

—
Redeemable common stock; $0.001 par value; 223,201 shares issued and outstanding; redemption value $900 at March 31, 2026 and $1,228 as of December 31, 2025 (Note 6)
900

1,228
Stockholders' deficit
 

 
Common stock, $0.001 par value per share; 1,000,000,000 shares authorized: and 1,265,067 shares issued and outstanding at both March 31, 2026 and December 31, 2025*
1

1
Preferred stock, $0.001 par value per share, 5,000,000 shares authorized: and no shares issued and outstanding at March 31, 2026 and December 31, 2025
—

—
Additional paid-in capital*
296,613

296,309
Accumulated deficit
(297,597)
(304,265)Total stockholders' deficit
(983)
(7,955)Total liabilities, redeemable common stock, and stockholders' deficit$4,838
$43,898
 *Adjusted retroactively to reflect the 1-for-18 reverse stock split that became effective on October 28, 2025.DNA X, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS EXCEPT SHARE AND PER SHARE AMOUNTS)
(UNAUDITED)

Three Months Ended March 31,

2026
2025
Continuing operations:

Net revenues$—
$—
Operating expenses

General and administrative
3,618

870
Total operating expenses
3,618

870
Net loss from operations
(3,618)
(870)Interest expense, net
(131)
(91)Loss on remeasurement of derivative liability
(227)
—
Equity income from DNA X LLC
48

—
Net loss from continuing operations before income taxes
(3,928)
(961)Income tax expense from continuing operations
—

—
Net loss from continuing operations
(3,928)
(961)Discontinued Operations:
 

 
Income from discontinued operations, net of tax
10,268

1,419
Net income$6,340
$458
Net earnings (loss) per share basic and diluted:
 

 
Continuing operations*
(3.11)
(2.96)Discontinued operations*
8.12

4.37
Net income*$5.01
$1.41
Weighted-average shares used in computing net loss per share:
 

 
Basic and diluted*
1,265,067

324,431
       *Adjusted retroactively to reflect the 1-for-18 reverse stock split that became effective on October 28, 2025. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/298202

Source: DNA X, Inc. (formerly Sonim Technologies Inc.)

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to make lead-optimization-quality decisions starting in hit identification

, /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that its Datapoints offering is launching ADME-One™, a fully integrated ADME platform for drug discovery teams co-developed with Tangible Scientific and Inductive Bio. ADME-One delivers a high-throughput Tier 1 ADME (absorption, distribution, metabolism, and excretion) panel paired with best-in-class AI-powered human pharmacokinetic (PK) projection and fully integrated compound management. The launch builds on the three companies' strategic partnership, announced in August 2025, to deploy AI-driven, lab-in-the-loop workflows across the biopharma industry. 

ADME-One is designed to break a cycle that has constrained small molecule drug discovery for decades: Due to the economic limitations of traditional data generation methods, comprehensive ADME profiling is typically reserved for lead optimization after teams have determined their lead series. When liabilities surface at this later stage, the cost of fixing them is highest. ADME-One changes that calculus, allowing discovery teams to characterize entire series with integrated, data-driven decisions in stages as early as hit identification. The result is fewer surprises, fewer wasted synthesis cycles, and a better ability to identify and test the compounds most likely to succeed in humans.

A Single, Integrated Workflow Across Three Category Leaders

ADME-One unites three best-in-class capabilities in one packaged service:

Ginkgo Datapoints: Data Generation. All five Tier 1 assays (microsomal stability, cell permeability, kinetic solubility, CYP inhibition, and plasma protein binding) are executed end-to-end in Ginkgo's automated laboratory in Boston. Validated, standardized workflows produce AI-ready data without the variability of manual handling. Inductive Bio: AI-Driven Contextualization. Inductive Bio's Compass platform turns the experimental panel into actionable human PK projections, integrating disparate individual ADME datapoints into a single multiparameter optimization endpoint that guides compound prioritization. The company's ADMET models are independently validated as best-in-class, having recently won both the 2025 ASAP and 2026 ExpansionRx OpenADMET blind prediction challenges, two of the most rigorous public benchmarks in the field. Tangible Scientific: Compound Management. Customers submit compounds and receive results. Tangible handles compound intake, plating, real-time tracking, and management for every ADME-One order, eliminating the logistics overhead that typically accompanies outsourced ADME work. Impact on Drug Discovery

"With ADME-One, we're both lowering the price of an ADME panel and transforming when and to what extent this data is effectively used in the drug discovery process," said John Androsavich, General Manager at Ginkgo Datapoints. "For the first time, chemists can efficiently characterize the entire series in hit identification. That fundamentally changes the quality of decisions teams make at the earliest stages of a program, where derisking is most needed. By combining automation, AI, and integrated logistics in a single domestic workflow, Ginkgo and our partners are demonstrating and making available the workflows that the Bio × AI era of drug discovery demands."

"We are at a moment in the application of AI to medicine where discovery teams can generate and prioritize drug candidates faster than their physical operations can validate them. Manifests get reconciled by hand, orders move through email threads, and senior scientists spend hours per week chasing shipments and tracking inventory across vendors. Tangible's role in ADME-One is to make the handoffs between design and data disappear, so discovery teams can validate candidates at the speed their AI investments promised," said Adham Chebbani, Co-founder of Tangible Scientific.

"The question every drug program is really trying to answer is which compound is most likely to achieve a safe and efficacious human dose," said Josh Haimson, CEO at Inductive Bio. "The Inductive platform lets drug hunters rank millions of compounds by predicted human dose, using state-of-the-art AI models that placed first in both OpenADMET competitions. With ADME-One, we move those compounds from the virtual lab to the wet lab in a tight feedback loop, surfacing the most promising ideas from day one. This is what AI-driven discovery looks like in practice: better decisions earlier, fewer dead ends later, and higher-quality medicines reaching patients sooner."

Together, the three partners deliver unified, contextualized ADME data in a streamlined workstream with rapid turnaround, all at a price point several times lower than the industry standard. Against the backdrop of U.S. and European drug developers reshoring preclinical efforts in response to the BIOSECURE Act and growing demand for data sovereignty, ADME-One delivers a fully U.S.-based workflow at pricing that beats offshore alternatives. Automated workflows return results in days rather than weeks, and because every run is standardized, each screening campaign contributes to better future predictions, delivering the volume, consistency, and metadata richness that AI-driven discovery depends on.

To drive ADME-One's product strategy, Ginkgo Datapoints has added Jonathan Grob to its leadership team as Vice President of Small Molecules. Grob brings deep expertise in medicinal chemistry, automation, and technology development from prior roles at Novartis and Valo Health. His hire reflects Ginkgo's continued investment in building the strongest next-generation, AI-enabled small molecule drug discovery team in the industry, complementing the platform's automation and data generation capabilities with seasoned scientific leadership.

Get Started on ADME-One

Drug discovery teams interested in early access or volume engagements are encouraged to contact Ginkgo Datapoints, Tangible Scientific, or Inductive Bio directly. Existing customers can contact their account representative to enable access to ADME-One. New customers can email [email protected] and visit our website at https://datapoints.ginkgo.bio/services#small-molecule-adme 

The three partners host the New England Drug Metabolism Discussion Group (NEDMDG) meeting on May 27 in Boston where they will share additional technical details, validation data, and customer case studies.

About Ginkgo Bioworks

Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo's in-house autonomous lab is also available as a "Cloud Lab" through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com, read our blog, or follow us on social media channels such as X (@Ginkgo), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.

About Tangible Scientific

Tangible Scientific is a tech-enabled compound management platform that removes the logistics bottleneck between design and data. From its Natick, MA facility, Tangible takes operational custody of customer compounds, handling storage, reformatting, plating, and same-day courier service to Boston-area partners including Ginkgo. AI-powered manifest reconciliation, real-time order tracking, and structured data return run through a single interface, giving discovery teams the quality of an in-house compound operation without the cost of building one. For more information, visit tangiblescientific.com.

About Inductive Bio

Inductive builds virtual chemistry labs that help drug hunters design higher quality molecules, faster. Inductive's virtual labs are designed to scale proven scientific best practices across medicinal chemistry, computational chemistry, DMPK, and safety, enabling teams to make higher-quality decisions consistently throughout discovery. Inside these virtual labs, AI chemistry assistants, predictive ADMET and PK models, and human-relevant digital organ technologies work together to help scientists evaluate more hypotheses in silico and surface key risks earlier. The most promising molecules move from the virtual lab to the wet lab in a tight feedback loop that accelerates the advancement of high-quality molecules. Inductive already powers dozens of active discovery programs, including collaborations with leading biopharma partners. For more information, please visit www.inductive.bio.

Forward-Looking Statements of Ginkgo Bioworks

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of Ginkgo's autonomous labs. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our platform programs and assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies, including potential adverse effects from the U.S. government shutdown. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 26, 2026, and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

INDUCTIVE BIO MEDIA CONTACT: [email protected]

SOURCE Inductive Bio, Inc.

BOULDER, Colo.--(BUSINESS WIRE)-- #ArcherAnalysis--IDT's library prep solutions join Illumina's extensive software ecosystem to enable streamlined analysis for IDT's FFPE and cfDNA workflows.

JPMorgan Chase and Co. boosted its position in shares of Park Hotels and Resorts Inc. (NYSE: PK) by 21.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,634,643 shares of the financial services provider's stock after purchasing

Posted by Defense World Staff on Apr 14th, 2026

Park Hotels & Resorts (NYSE:PK – Get Free Report) and National Storage Affiliates Trust (NYSE:NSA – Get Free Report) are both mid-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, dividends and analyst recommendations.

Dividends Park Hotels & Resorts pays an annual dividend of $1.00 per share and has a dividend yield of 9.0%. National Storage Affiliates Trust pays an annual dividend of $2.28 per share and has a dividend yield of 5.5%. Park Hotels & Resorts pays out -69.9% of its earnings in the form of a dividend. National Storage Affiliates Trust pays out 330.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Park Hotels & Resorts has increased its dividend for 1 consecutive years and National Storage Affiliates Trust has increased its dividend for 1 consecutive years. Park Hotels & Resorts is clearly the better dividend stock, given its higher yield and lower payout ratio.

Profitability This table compares Park Hotels & Resorts and National Storage Affiliates Trust’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Park Hotels & Resorts -11.14% -8.56% -3.30% National Storage Affiliates Trust 9.80% 5.81% 1.43% Institutional & Insider Ownership 92.7% of Park Hotels & Resorts shares are held by institutional investors. Comparatively, 100.0% of National Storage Affiliates Trust shares are held by institutional investors. 2.5% of Park Hotels & Resorts shares are held by insiders. Comparatively, 13.7% of National Storage Affiliates Trust shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation This table compares Park Hotels & Resorts and National Storage Affiliates Trust”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Park Hotels & Resorts $2.54 billion 0.88 -$283.00 million ($1.43) -7.81 National Storage Affiliates Trust $752.93 million 4.24 $73.78 million $0.69 60.04 National Storage Affiliates Trust has lower revenue, but higher earnings than Park Hotels & Resorts. Park Hotels & Resorts is trading at a lower price-to-earnings ratio than National Storage Affiliates Trust, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations This is a breakdown of recent ratings and target prices for Park Hotels & Resorts and National Storage Affiliates Trust, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Park Hotels & Resorts 3 8 2 0 1.92 National Storage Affiliates Trust 1 12 0 0 1.92 Park Hotels & Resorts currently has a consensus target price of $11.45, indicating a potential upside of 2.54%. National Storage Affiliates Trust has a consensus target price of $33.60, indicating a potential downside of 18.89%. Given Park Hotels & Resorts’ higher possible upside, equities research analysts clearly believe Park Hotels & Resorts is more favorable than National Storage Affiliates Trust.

Risk and Volatility Park Hotels & Resorts has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Comparatively, National Storage Affiliates Trust has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.

Summary National Storage Affiliates Trust beats Park Hotels & Resorts on 9 of the 15 factors compared between the two stocks.

About Park Hotels & Resorts (Get Free Report)

Park Hotels & Resorts, Inc. operates as a real estate investment trust, which owns and operates hotels and resorts. It operates through the Consolidated Hotels and Unconsolidated Hotels segments. Its portfolio of hotels and resorts include the Waldorf Astoria Hotels and Resorts, Conrad Hotels & Resorts, Hilton Hotels & Resorts, DoubleTree by Hilton, Embassy Suites by Hilton, Hilton Garden Inn, Hampton by Hilton, and Curio. The company was founded by Conrad Hilton in 1919 and is headquartered in Tysons, VA.

About National Storage Affiliates Trust (Get Free Report)

National Storage Affiliates Trust is a real estate investment trust headquartered in Greenwood Village, Colorado, focused on the ownership, operation and acquisition of self storage properties predominantly located within the top 100 metropolitan statistical areas throughout the United States. As of December 31, 2023, the Company held ownership interests in and operated 1,050 self storage properties, located in 42 states and Puerto Rico with approximately 68.6 million rentable square feet, which excludes 39 self storage properties classified as held for sale to be sold to a third party. NSA is one of the largest owners and operators of self storage properties among public and private companies in the United States.

Receive News & Ratings for Park Hotels & Resorts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Park Hotels & Resorts and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEiShares Expanded Tech-Software Sector ETF Target of Unusually High Options Trading (BATS:IGV)

NEXT HEADLINE »Traders Purchase High Volume of Allogene Therapeutics Call Options (NASDAQ:ALLO)

Posted by Defense World Staff on Apr 27th, 2026

Cwm LLC lowered its position in shares of Park Hotels & Resorts Inc. (NYSE:PK – Free Report) by 27.2% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 123,709 shares of the financial services provider’s stock after selling 46,222 shares during the quarter. Cwm LLC owned about 0.06% of Park Hotels & Resorts worth $1,294,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Danske Bank A S bought a new position in Park Hotels & Resorts during the third quarter worth about $25,000. Advisory Services Network LLC bought a new stake in Park Hotels & Resorts in the 3rd quarter valued at about $34,000. Clearstead Advisors LLC boosted its holdings in Park Hotels & Resorts by 326.4% in the 3rd quarter. Clearstead Advisors LLC now owns 3,198 shares of the financial services provider’s stock valued at $35,000 after purchasing an additional 2,448 shares during the period. Harbor Capital Advisors Inc. grew its position in shares of Park Hotels & Resorts by 293.1% during the 4th quarter. Harbor Capital Advisors Inc. now owns 5,181 shares of the financial services provider’s stock worth $54,000 after purchasing an additional 3,863 shares in the last quarter. Finally, Allworth Financial LP grew its position in shares of Park Hotels & Resorts by 56.5% during the 3rd quarter. Allworth Financial LP now owns 6,136 shares of the financial services provider’s stock worth $68,000 after purchasing an additional 2,216 shares in the last quarter. Institutional investors own 92.69% of the company’s stock.

Park Hotels & Resorts Price Performance Shares of NYSE:PK opened at $11.19 on Monday. The firm has a 50 day moving average of $10.92 and a 200-day moving average of $10.89. Park Hotels & Resorts Inc. has a 12 month low of $9.57 and a 12 month high of $12.39. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 1.25. The stock has a market capitalization of $2.25 billion, a PE ratio of -7.83 and a beta of 1.39.

Park Hotels & Resorts (NYSE:PK – Get Free Report) last posted its quarterly earnings results on Thursday, February 19th. The financial services provider reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($1.50). The firm had revenue of $629.00 million for the quarter, compared to analyst estimates of $621.79 million. Park Hotels & Resorts had a negative return on equity of 8.56% and a negative net margin of 11.14%.The business’s revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.39 EPS. Park Hotels & Resorts has set its FY 2026 guidance at 1.730-1.89 EPS. On average, equities research analysts predict that Park Hotels & Resorts Inc. will post 1.76 EPS for the current fiscal year.

Park Hotels & Resorts Dividend Announcement The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Tuesday, March 31st were issued a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 8.9%. The ex-dividend date of this dividend was Tuesday, March 31st. Park Hotels & Resorts’s dividend payout ratio (DPR) is currently -69.93%.

Wall Street Analyst Weigh In A number of equities research analysts have recently weighed in on the stock. Truist Financial lifted their price target on shares of Park Hotels & Resorts from $11.00 to $12.00 and gave the company a “hold” rating in a research report on Thursday, March 26th. Wall Street Zen raised Park Hotels & Resorts from a “sell” rating to a “hold” rating in a research report on Sunday, March 1st. Barclays restated an “equal weight” rating and set a $9.00 price objective (down from $13.00) on shares of Park Hotels & Resorts in a research note on Tuesday, April 7th. Cantor Fitzgerald lifted their price objective on Park Hotels & Resorts from $11.00 to $12.00 and gave the company a “neutral” rating in a report on Tuesday, March 3rd. Finally, JPMorgan Chase & Co. upped their target price on Park Hotels & Resorts from $10.00 to $11.00 and gave the company an “underweight” rating in a research report on Tuesday, February 3rd. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $11.45.

Check Out Our Latest Research Report on PK

Park Hotels & Resorts Profile (Free Report)

Park Hotels & Resorts Inc is a publicly traded real estate investment trust (REIT) specializing in luxury and upper-upscale hospitality properties. The company’s primary business activity involves owning and leasing premier hotels and resorts across major urban and resort destinations. Through long-term management and franchise agreements with leading hotel operators, Park generates revenue from room nights, food and beverage offerings, meetings and events, and ancillary services.

Since its spin-off from Hilton Worldwide in January 2017, Park Hotels & Resorts has assembled a diversified portfolio of more than 60 properties.

Further Reading Five stocks we like better than Park Hotels & Resorts Want to see what other hedge funds are holding PK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Park Hotels & Resorts Inc. (NYSE:PK – Free Report).

Receive News & Ratings for Park Hotels & Resorts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Park Hotels & Resorts and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECheniere Energy, Inc. $LNG Shares Sold by Cwm LLC

NEXT HEADLINE »Evergreen Capital Management LLC Invests $456,000 in Teck Resources Ltd $TECK

TYSONS, Va.--(BUSINESS WIRE)---- $PK--Park Hotels & Resorts Inc. (“Park” or the “Company”) (NYSE: PK) today announced results for the first quarter ended March 31, 2026 and provided an operational update and an update on its Non-Core hotel disposition initiative. First Quarter Highlights Include: Comparable RevPAR was $191.05, an increase of 2.2% compared to the same period in 2025, or a 5.5% increase when excluding the Royal Palm South Beach Miami, a Tribute Portfolio Resort (“Royal Palm”), which.

For the quarter ended March 2026, Park Hotels & Resorts (PK - Free Report) reported revenue of $622 million, down 1.3% over the same period last year. EPS came in at $0.45, compared to -$0.29 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $618.44 million, representing a surprise of +0.58%. The company delivered an EPS surprise of +11.94%, with the consensus EPS estimate being $0.40.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Park Hotels & Resorts performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Comparable RevPAR Growth: 2.2% compared to the 0.9% average estimate based on three analysts.Total Number of rooms: 20,467 versus 21,404 estimated by two analysts on average.Comparable RevPAR: $191.05 million versus $183.16 million estimated by two analysts on average.Revenues- Rooms: $356 million compared to the $348.41 million average estimate based on three analysts. The reported number represents a change of -1.9% year over year.Revenues- Ancillary hotel: $60 million compared to the $62.63 million average estimate based on two analysts. The reported number represents a change of -4.8% year over year.Revenues- Food and beverage: $182 million compared to the $181.69 million average estimate based on two analysts. The reported number represents a change of 0% year over year.Revenues- Other: $24 million versus the two-analyst average estimate of $22.11 million. The reported number represents a year-over-year change of +9.1%.Earnings per share - Diluted: $0.05 compared to the $0.04 average estimate based on three analysts.View all Key Company Metrics for Park Hotels & Resorts here>>>

Shares of Park Hotels & Resorts have returned +9.3% over the past month versus the Zacks S&P 500 composite's +12.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

TYSONS, Va.--(BUSINESS WIRE)---- $PK--Park Hotels & Resorts Inc. (NYSE: PK) (“Park”) today announced that it plans to report financial results for the second quarter 2026 after the stock market closes on Thursday, August 6, 2026. Park will hold a conference call on Friday, August 7, 2026, at 11:00 a.m. Eastern Time (ET) to discuss its earnings results, current operational environment and business outlook. The conference call will be accessible by telephone and through the internet. Interested indiv.

The benefit of the Federal Reserve lowering interest rates may not happen until late this year, if at all. Even so, listed real estate investment trusts (REITs) are delivering for investors.

Read more: Green Shoots Emerging in the Real Estate Sector

For example, the largest real estate ETF is higher by 8.60% year-to-date, but the ALPS REIT Dividend Dogs ETF (RDOG) far exceeds that. RDOG is up 14.38% since the start of 2026, outpacing its larger rival and the broader market in the process. The ETF, which tracks the S-Network REIT Dividend Dogs Index, turned 18 years old last month. It’s outperforming with a trailing 12-month yield of 6.14% — above-average in a category known for its potent income streams.

Of course, RDOG’s bullishness is aided by holding the right REITs, including Park Hotels & Resorts (PK), the ETF’s fourth-largest holding and a stock that some experts view as offering value.

“Park Hotels & Resorts holds the first spot as the least expensive company on our list of the best REITs to buy, trading 34% below our fair value estimate of $19.50 per share,” noted Morningstar’s Tori Brovet. “Park Hotels & Resorts owns upper-upscale and luxury hotels, with 21,042 rooms across 33 hotels in the United States. It also offers the highest REIT forward dividend yield on our list at 7.75%.”

Not a Gamble, But… RDOG embodies the defensive spirit of the real estate sector. Neither the sector nor the ETF are “gambles” in the true sense of that word. However, the ETF could benefit from goings on in the casino world, because Vici Properties (VICI) and Gaming and Leisure Properties (GLPI) — the two largest owners of casino real estate — are RDOG member firms.

Amid a spate of large-scale consolidation activity in that space, including Barry Diller offering $18 billion for MGM Resorts (MGM) and Tilman Fertitta bidding $17.6 billion for Caesars Entertainment (CZR), analysts see avenues for the two RDOG holdings to benefit.

That would likely come from the REITs diversifying tenant rosters or adding properties to their portfolios. At the same time, large acquired companies could potentially shed some assets.

“Another potential consequence of the CZR deal, in our view, is potential pickup in M&A interest from proven (mid-tier) operators that could already be in the process of arranging financing for some properties believed to be under operated. VICI also sees intriguing opportunity with the mix of brands under the CZR’s umbrella, that could extract value if prioritized,” observed Truist analyst Barry Jonas.

For more news, information, and analysis, visit the ETF Building Blocks Content Hub.

Vettafi.com is owned by VettaFi LLC (“VettaFi”). VettaFi is the index provider for RDOG for which it receives an index licensing fee. However, RDOG is not issued, sponsored, endorsed, or sold by VettaFi. VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of RDOG.

PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, announced positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo™ (SPT-320), a novel, Glyphed oral prodrug of agomelatine, in healthy volunteers. Repeat dosing of GlyphAgo demonstrated a safety, tolerability, and pharmacokinetic (PK) profile consistent with previously reported single-ascending dose (SAD) and crossover data, supporting its planned advancement of GlyphAgo into two parallel Phase 2 trials in patients with generalized anxiety disorder (GAD).

Seaport expects to initiate a Phase 2a proof-of pharmacology trial in the second half of 2026. This randomized, double-blind trial of two dose levels of GlyphAgo is designed to demonstrate proof-of-pharmacology by characterizing the potential benefits of GlyphAgo on sleep, including objective measures of sleep architecture, in patients with GAD and sleep disturbance. Topline data from this trial are expected in early 2028.

Seaport also expects to initiate a Phase 2b trial of GlyphAgo in the first half of 2027. This randomized, double-blind, placebo-controlled, potentially registration-enabling trial is designed to evaluate the efficacy and safety of GlyphAgo in patients with GAD. Topline data from this trial are expected by the end of 2028.

The GlyphAgo program and the underlying Glyph platform were initially advanced at PureTech, applying the Company’s strategy of identifying clinically validated pharmacology and overcoming key limitations through targeted innovation. The Glyph platform and related programs are now being advanced by PureTech’s Founded Entity, Seaport Therapeutics.

The full text of the announcement from Seaport is as follows:

Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Repeat dosing of GlyphAgo confirms favorable safety, tolerability, and pharmacokinetics observed across the Phase 1 program, with no liver-related adverse events observed

New data demonstrate seven-day dosing of GlyphAgo achieved therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing

Results support dose selection and planned advancement into two parallel Phase 2 trials in patients with generalized anxiety disorder

BOSTON, June 8, 2026 -- Seaport Therapeutics, Inc., (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo™ (SPT-320), a novel, Glyphed oral prodrug of agomelatine, in healthy volunteers. Repeat dosing of GlyphAgo demonstrated a safety, tolerability, and pharmacokinetic (PK) profile consistent with previously reported single-ascending dose (SAD) and crossover data, supporting its planned development in patients with generalized anxiety disorder (GAD).

The MAD data showed that seven-day dosing of GlyphAgo achieved therapeutic exposures of agomelatine at doses that reduce liver exposure and are projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing that has previously limited agomelatine’s clinical use. GlyphAgo AUC0-24 and Cmax increased dose-dependently over the range of doses studied, and agomelatine exposures following GlyphAgo administration in the MAD portion were consistent with data from the SAD and crossover portions of the trial. There was no unmodified agomelatine arm in the MAD portion.

Across all dose levels evaluated, GlyphAgo was well tolerated, with no serious or severe adverse events, no liver-related adverse events, and no clinically significant changes in liver-related laboratory parameters observed, further supporting observations from the SAD and crossover cohorts.

“We are enthusiastic about the data from our Phase 1 program for GlyphAgo, where we’ve now observed consistent safety, tolerability, and PK across all cohorts,” said Daphne Zohar, Co-Founder and Chief Executive Officer of Seaport Therapeutics. “We believe these results substantially derisk our future clinical development approach and strengthen the differentiated profile of GlyphAgo. The complete Phase 1 data package further validates our Glyph platform and supports the advancement of GlyphAgo into two parallel Phase 2 trials as we work to bring a new treatment option to patients with generalized anxiety disorder who have not had a new medicine approved in almost 20 years.”

The Phase 1 proof-of-concept trial, which included 174 participants, was conducted in multiple parts to evaluate the safety, tolerability, and PK of GlyphAgo and to compare the PK of GlyphAgo to agomelatine alone. The trial included SAD and MAD cohorts, as well as a crossover portion (including both food-effect and within-participant comparison between GlyphAgo and agomelatine), using both open-label and placebo-controlled designs.

In the previously reported results from the head-to-head crossover portion of the trial, GlyphAgo demonstrated a 6.8-fold increase in bioavailability of agomelatine compared with orally administered unmodified agomelatine. GlyphAgo also showed significantly lower (10-fold) PK variability compared to unmodified agomelatine. The crossover portion included participants who were taking estrogen-containing oral contraceptives that are known to increase agomelatine exposure due to liver drug-drug interaction. In contrast, GlyphAgo exposure was unaffected by oral contraceptives, further supporting the ability of GlyphAgo to bypass first-pass liver metabolism. GlyphAgo demonstrated a 9.6 to 14.5-fold increase in dose-normalized exposure compared to agomelatine in a separate SAD portion of the trial in which no participants were on oral contraceptives.

Seaport expects to initiate a Phase 2a proof-of pharmacology trial in the second half of 2026. This randomized, double-blind trial of two dose levels of GlyphAgo is designed to demonstrate proof-of-pharmacology by characterizing the potential benefits of GlyphAgo on sleep, including objective measures of sleep architecture, in patients with GAD and sleep disturbance. Topline data from this trial are expected in early 2028. Seaport also expects to initiate a Phase 2b trial of GlyphAgo in the first half of 2027. This randomized, double-blind, placebo-controlled, potentially registration-enabling trial is designed to evaluate the efficacy and safety of GlyphAgo in patients with GAD. Topline data from this trial are expected by the end of 2028. Seaport plans to present additional analyses from the Phase 1 trial at future upcoming scientific meetings.

About GlyphAgo™ (SPT-320 or Glyph Agomelatine)
GlyphAgo is a novel, “Glyphed” oral prodrug of agomelatine, a clinically validated anti-anxiety and antidepressant that is approved for the treatment of GAD in Australia and Major Depressive Disorder in Australia and the European Union. Using Seaport’s proprietary Glyph™ platform, GlyphAgo is designed to enhance lymphatic absorption and avoid first-pass liver metabolism, thereby enhancing oral bioavailability and reducing side effects. By leveraging an alternative absorption pathway via the intestinal lymphatic system used by dietary fats, GlyphAgo is designed to increase systemic exposure of agomelatine, enabling exposure levels of agomelatine that are effective in GAD but at a lower dose that reduces liver exposure and reduces or eliminates the need for liver function testing. Based on the data generated to date, Seaport believes GlyphAgo has the potential to become a leading treatment for GAD.

About Seaport Therapeutics
Seaport Therapeutics (Nasdaq: SPTX) is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through its differentiated approach, the Company identifies clinically validated mechanisms with established efficacy and safety which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. Seaport applies its proprietary Glyph™ platform to overcome those limitations and invent innovative oral therapies. With an experienced team of industry leaders, Seaport has a proven track record in neuropsychiatry drug discovery and development and delivering successful business outcomes. Seaport aims to develop novel, leading treatment options that will make a significant impact for patients and their families. For more information, please visit www.seaporttx.com.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding our product candidates, preclinical and clinical development activities and timelines, including projected data announcements, and our expectations for future operations and financial performance. These statements include, among other things, Seaport Therapeutics’ expectations regarding the concurrent Phase 2 trials of GlyphAgo (SPT-320), including the expected trial design and the timing of topline data.

Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect Seaport Therapeutics’ business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the Company’s research and development activities; Seaport Therapeutics’ ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the Company’s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; Seaport Therapeutics’ ability to attract, integrate and retain key personnel; risks related to the Company’s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining Seaport Therapeutics’ intellectual property protections; and risks related to the competitive landscape for Seaport Therapeutics’ product candidates; as well as other risks described in “Risk Factors,” in Seaport Therapeutics’ Registration Statement on Form S-1 filed with the Securities and Exchange Commission (SEC), as well as subsequent filings with the SEC. Seaport Therapeutics expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Seaport uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company’s Investor Relations website, in addition to following the Company’s press releases, SEC filings, public conference calls, presentations, and webcasts.

About PureTech Health
PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders.

For more information, visit www.puretechhealth.com or connect with us on LinkedIn and X (formerly Twitter) @puretechh.

Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to those related to Seaport's development plans for its pipeline of neuropsychiatric therapeutics based on the Glyph™ Platform, the potential of GlyphAgo™ (SPT-320™ or Glyph Agomelatine) and the Glyph platform, the broader applicability of the platform, the addressable market for Seaport's product candidates, if approved, potential benefits to patients, and Seaport's and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260608428399/en/

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.

On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.

One company to watch right now is Park Hotels & Resorts (PK - Free Report) . PK is currently holding a Zacks Rank #2 (Buy) and a Value grade of A. The stock is trading with a P/E ratio of 5.89, which compares to its industry's average of 16.85. Over the past year, PK's Forward P/E has been as high as 7.11 and as low as 4.38, with a median of 5.77.

PK is also sporting a PEG ratio of 1.37. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. PK's industry has an average PEG of 1.62 right now. PK's PEG has been as high as 6.29 and as low as 0.61, with a median of 1.28, all within the past year.

Another valuation metric that we should highlight is PK's P/B ratio of 0.71. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. This stock's P/B looks attractive against its industry's average P/B of 1.97. PK's P/B has been as high as 0.88 and as low as 0.52, with a median of 0.70, over the past year.

Finally, investors should note that PK has a P/CF ratio of 6.18. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. This company's current P/CF looks solid when compared to its industry's average P/CF of 15.39. Within the past 12 months, PK's P/CF has been as high as 6.25 and as low as 4.43, with a median of 5.21.

Value investors will likely look at more than just these metrics, but the above data helps show that Park Hotels & Resorts is likely undervalued currently. And when considering the strength of its earnings outlook, PK sticks out as one of the market's strongest value stocks.